cb1/2 agonist 2

CB1/2 agonist 2 (compound 23) 是一种有效的非选择性大麻素 (cannabinoid) 配体，其Ki 分别为 3.5 nM 和 1.2 nM。CB1/2 agonist 2 是一种 CB1 的完全激动剂，也是 CB2 竞争性反向激动剂。CB1/2 agonist 2 表现出抗伤害效果。

CB1/2 agonist 3 是一种具有竞争性和高效性的 CB1/CB2 激动剂，对 hCB1 和 hCB2 具有很高的亲和力，可用于研究神经系统疾病。

CB1/2 agonist 4 (compound 24) 是一种 CB1 完全激动剂 (EC50: 15.09 nM) ，也是一种 CB2 部分激动剂 (EC50: 1.16 nM)。CB1/2 agonist 4 具有显著的抗伤害感受活性，也能够激活大麻素和TRPV1受体 (IC50: 0.8 μM, EC50: 0.12 μM)。

CB1/2 agonist 1 是一种有效的、能够透过血脑屏障的 CB1/2 激动剂，能够作用于 CB1R (EC50: 56.15 nM) 和 CB2R (EC50: 11.63 nM)。CB1/2 agonist 1 能够降低谷氨酸释放，并减少 LPS 诱导的小胶质细胞活化，具有抗炎和镇痛活性。CB1/2 agonist 1 具有潜力进行多发性硬化症的研究。

CB1inverse agonist 2 是一种口服有效的大麻素受体 CB1反向激动剂。CB1inverse agonist 2 在小鼠模型中，能有效抑制 CP55940 导致的体温失温和厌食情况。

GP 1a 是cannabinoid receptor 2（CB2）的强效激动剂（EC50=7.1),是在cAMP、GTPγS 和β-arrestin 招募试验中显示的。GP 1a 对CB2受体的选择性约为CB1受体的30倍，且在体外增加HL-60细胞的P-ERK1/2表达。GP 1a 对皮肤伤口愈合有益。GP 1a 可抑制炎症和纤维生成，同时促进上皮的重新形成。

Tedalinab is an effective and selective cannabinoid receptor 2 agonist. Tedalinab has the potential for neuropathic pain and osteoarthritis treatment. Tedalinab has >4700-fold functional selectivity for CB2 over CB1.

Compound 5.3 (CB1/2 receptor-1)为CB1/2受体激动剂，常用于血管生成领域的研究。

SCH-336是一种 CB2受体激动剂(Ki-1.8 nM, EC50-2 nM)，具有有效性，选择性和口服活性。SCH-336对 CB1受体也具有生物活性，对CB2受体的选择性是CB1的100倍。SCH-336能够减少鸟苷5'-3- o -(硫)三磷酸与含hCB 的膜的结合，抑制 BaF3/CB2 细胞迁移，抑制小鼠延迟型超敏反应模型中的白细胞迁移，抑制小鼠过敏模型中抗原诱导的肺嗜酸性粒细胞增多。

LEI-101 是有效的、选择性的、具有口服活性的大麻素CB2受体激动剂。LEI-101对 hCB2 的 pEC50值为 8，对 hERG 的 pKi 值小于 4。LEI-101 与 CB2 受体的结合能力比 CB1 强100 倍。LEI-101 具有炎症及氧化应激相关疾病的治疗潜力。

(±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). It is produced through direct epoxygenation of docosahexaenoyl ethanolamide by cytochrome P450 (CYP) epoxygenases. (±)19(20)-EDP ethanolamide (25 μM) reduces the viability of 143B metastatic osteosarcoma cells. It decreases the production of IL-6 and increases the production of IL-10 when used at concentrations ranging from 2.5 to 10 μM in BV-2 microglia stimulated by LPS and decreases LPS-induced cytotoxicity when used at concentrations ranging from 5 to 10 μM. It also decreases nitrite production when used at a concentration of 7.5 μM, an effect that can be partially reversed by the CB2 receptor antagonist AM630 and the PPARγ antagonist GW 9662 . (±)19(20)-EDP ethanolamide induces vasodilation of isolated preconstricted bovine coronary arteries (ED50 = 1.9 μM) and reduces tube formation by human microvascular endothelial cells (HMVECs) in a Matrigel assay.

Noladin ether (2-AG ether) 是一种具有选择性和高效性的大麻素 CB1 受体激动剂，通过非 CB1/CB2 G（i/o） 连接受体减弱大鼠离体肠系膜动脉床中的感觉神经传递，以浓度依赖性方式减弱感觉神经源性松弛。

2-arachidonyl glycerol (2-AG) exhibits cannabinoid (CB) agonist activity at the CB1 receptor, is an important endogenous monoglyceride species, and is thus considered to be the natural ligand for the CB1 receptor. 2-AG can also be metabolized by cyclooxygenase-2 and specific prostaglandin H2 (PGH2) isomerases to form PG 2-glyceryl esters. Fluprostenol serinol amide (Flu-SA) is a stable analog of PGF2α 2-glyceryl ester that has much greater stability. The biological activity of Flu-SA has not yet been determined.

Arachidonoyl 2-chloroethylamide (ACEA) is a potent and selective cannabinoid (CB) receptor 1 agonist with Ki values of 1.4 and >2,000 nM for CB1 and CB2 receptors, respectively. In whole animal experiments, ACEA induces hypothermia in mice with the same efficacy as arachidonoyl ethanolamide , in spite of its higher affinity for the CB1 receptor. These data have been interpreted to indicate that ACEA may be a substrate for fatty acid amide hydrolase (FAAH), and thus only transiently available in whole animal experiments.

(±)-WIN 55,212-2 is a potent aminoalkylindole cannabinoid (CB) receptor agonist with a Ki value of 62.3 and 3.3 nM for human recombinant central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, respectively. In contrast, the enantiomer (-)-WIN 55,212-3 acts a partial inverse agonist at CB1 (pIC50 = 5.5) and as a competitive neutral antagonist of CB2, reversing the inverse agonism evoked by SR 144528 (pEC50 = 5.3). (+)-WIN 55,212 (mesylate) is a mixture of the two enantiomers, (+)-WIN 55,212-2 and (-)-WIN 55,212-3.

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(-) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB1 full agonist CP 55,940 to CHO cells expressing human recombinant CB1 (hCB1), as well as the activity of 2-arachidonoyl glycerol , arachidonoyl ethanolamide , and CP 55,940 in arrestin2 recruitment assays and increases ERK1/2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB1. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons. GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.

WIN 55,212-2 Mesylate ((R)-(+)-WIN 55212) 是 cannabinoid receptor 激动剂，对人重组 CB1 受体(Ki:62.3 nM) 和 CB2 受体 (Ki:3.3 nM)。

CBR Agonist-2 是一种 CB1 激动剂 (EC50: 960 nM)(Ki: 970 nM)(CB1R; CB1 配体)。CBR Agonist-2 是一种很有前景的工具，能够用于 hCB1R 参与的内源性大麻素系统相关疾病的研究。

BML-190 (Indomethacin morpholinylamide) 是一种 CB2 受体的配体，其对 CB2 受体 (Ki:435 nM) 和 CB1受体 (Ki> 2 μM)。

GW842166X 是一种选择性 cannabinoid receptor 2 激活剂，IC50=63 nM。

AMG-315 is a Potent Endocannabinoid Ligand with Stability to Metabolizing Enzymes. AMG-315 is a chiral arachidonoyl ethanolamide (AEA) analogue or (13S,1′R)-dimethylanandamide. AMG-315 is a high affinity ligand for the CB1 receptor (Ki of 7.8 ± 1.4 nM) that behaves as a potent CB1 agonist in vitro (EC50 = 0.6 ± 0.2 nM). AMG-315 is the first potent AEA analogue with significant stability for all endocannabinoid hydrolyzing enzymes as well as the oxidative enzymes COX-2. AMG-315 will serve as a very useful endocannabinoid probe.

LY2828360 是一种作用缓慢的、有效的 G 蛋白偏倚的大麻素受体 2(CB2)激动剂，能够抑制 cAMP 的积累并激活 ERK1/2 通路。

Hemopressin(rat) TFA，一种衍生自α1-珠蛋白九肽，最初分离自大鼠脑匀浆。该化合物通过口服能有效选择性地作为CB1大麻素受体的反向激动剂，并在炎性疼痛模型中表现出抗伤害感受活性。

Hemopressin TFA，一种衍生自血红蛋白α1链的九肽，最初自大鼠脑匀浆分离。作为口服活性且选择性的CB1大麻素受体反向激动剂，Hemopressin TFA在炎性疼痛模型中具有抗伤害感受效应。